Cancer treatment and research communications最新文献

{"title":"Pinkbar elevation in colon cancer patients and the therapeutic effects of hAMSCs secretome through AKT/mTOR and Wnt3a/β-catenin signaling pathways in HT-29 colon cancer cells","authors":"Fatemeh Safari,&nbsp;Danial Hassas Khodravesh,&nbsp;Nasim Shafiee Nejad,&nbsp;Laleh Mirzanejad","doi":"10.1016/j.ctarc.2026.101331","DOIUrl":"10.1016/j.ctarc.2026.101331","url":null,"abstract":"<div><div>Cancer is a major cause of human death. Colon cancer is the fifth leading cause of cancer-related deaths worldwide. Pinkbar, a member of the inverse BAR (I-BAR) domain protein subfamily, is associated with the actin cytoskeleton, leading to cell motility and cell shape changes. We focused on <em>Pinkbar</em> expression in colon cancer patients and explored the therapeutic effects of human amniotic mesenchymal stem cells (hAMSCs) secretome on Pinkbar expression in colon cancer cells through AKT/mTOR and Wnt3a/β-catenin signaling pathways. Thirty colon cancer specimens were collected, and <em>Pinkbar</em> expression was assessed using quantitative real-time PCR (qRT-PCR). A co-culture system with 6-well Transwell plates was utilized to treat HT-29 cells with hAMSCs secretome, followed by analysis of cell proliferation and invasion through qRT-PCR, MTT assay, Western blot, DAPI staining, and wound healing assay. Our results demonstrated up-regulation of <em>Pinkbar</em> in colon cancer patients and inhibition of Pinkbar, p-AKT (Thr308), p-mTOR (Ser2481), Wnt3a, β-catenin, p-P70S6K (Ser411), and cyclin D1 expression along with an increase in E-cadherin levels in hAMSCs-treated HT-29 colon cancer cells. These results suggest that Pinkbar may serve as a potential target for colon cancer therapy, and hAMSCs secretome can effectively inhibit colon cancer cell proliferation and invasion through AKT/mTOR and Wnt3a/β-catenin signaling pathways.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101331"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of underwater endoscopic mucosal resection (UEMR) for non-pedunculated colorectal polyps: a prospective study IN Vietnam","authors":"Tran Kinh Thanh,&nbsp;Nguyen Trong Man Dat,&nbsp;Huynh Dao Nhat Huy,&nbsp;Tran Vy Thao,&nbsp;Phi Duong Nguyen","doi":"10.1016/j.ctarc.2026.101290","DOIUrl":"10.1016/j.ctarc.2026.101290","url":null,"abstract":"<div><h3>Introduction</h3><div>Colorectal cancer is a leading cause of global malignancy and mortality. While conventional endoscopic mucosal resection (CEMR) is the standard for removing premalignant lesions, it requires submucosal injection. Underwater EMR (UEMR) eliminates the need for injection by utilizing water immersion to achieve mucosal separation and lesion buoyancy. Prospective data from resource-limited healthcare settings like Vietnam remain scarce.</div></div><div><h3>Methods</h3><div>This prospective observational study was conducted at 115 People's Hospital, Ho Chi Minh City, from May to July 2025. We consecutively enrolled adults with non-pedunculated colorectal polyps measuring 10–25 mm. UEMR was performed via water immersion without routine submucosal lifting injection using an Endo Cut Q mode (ERBE VIO 200D). Primary outcomes were en bloc and R0 resection rates. Secondary outcomes included adverse events such as bleeding and perforation.</div></div><div><h3>Results</h3><div>The mean age of participants was 52.6 ± 14.2 years, with 66.7% being male. The average polyp size was 13.7 ± 5.1 mm. Most polyps were located in the rectum (35.9%) and sigmoid colon (25.6%). En bloc resection was achieved in 87.2% of cases, and histologic R0 resection in 84.6%. Immediate bleeding occurred in 5.1% (2/39) of cases, all managed successfully with endoscopic clipping. No delayed bleeding, perforation, or post-polypectomy syndrome was observed.</div></div><div><h3>Conclusions</h3><div>UEMR is a highly effective and safe modality for resecting intermediate-sized non-pedunculated colorectal polyps in Vietnam. The high en bloc and R0 resection rates and low adverse event profile support its integration into routine practice, particularly in resource-constrained environments where cost-effectiveness and technical simplicity are essential.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101290"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148257402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Projected disease burden and treatment eligibility of patients with diffuse large B-cell and mantle cell lymphoma in the United States over the next decade","authors":"Dan Lin,&nbsp;Changxia Shao,&nbsp;Jiemin Ma,&nbsp;Mehmet Burcu,&nbsp;Helmneh M. Sineshaw","doi":"10.1016/j.ctarc.2026.101291","DOIUrl":"10.1016/j.ctarc.2026.101291","url":null,"abstract":"<div><h3>Introduction</h3><div>There is lack of comprehensive and up-to-date forecasted estimates for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), with inconsistencies in existing literature. The study estimated and forecasted incidence, prevalence, and treatment-eligible patient counts by line of therapy (LoT) for DLBCL and MCL in the US from 2023 to 2032.</div></div><div><h3>Methods</h3><div>Historical incidence rates for 2017-2022 (excluding 2020) from SEER-21 were used for projections. A validated joinpoint regression model forecasted age- and gender-specific incidence rates. A validated prevalence model incorporating incidence, survival, and cure likelihood estimated 5-, 10-, 15-, and 20-year prevalences. A new model estimated treatment-eligible DLBCL and MCL patients counts by LoT, integrating projected incidence, literature estimates on re‑entry patients, and SEER-Medicare treatment‑pattern data.</div></div><div><h3>Results</h3><div>From 2023 to 2032, DLBCL incidence is projected to rise by 7% (28,838 to 30,772) and MCL by 6% (3,377 to 3,589). The 5-, 10-, 15-, and 20-year prevalences are expected to increase by 11%, 16%, 18%, and 20% for DLBCL, and by 8%, 13%, 16%, and 19% for MCL. In DLBCL, treatment-eligible patients are estimated to increase by 7% in 1L (33,120 to 35,523) and by 8% in later lines (2L: 9,243 to 9,976; 3L: 4,466 to 4,821; 4L: 2,163 to 2,335). In MCL, treatment-eligible patients are expected to increase by 6% across all LoT (1L: 3,376 to 3,591; 2L: 1,220 to 1,297; 3L: 685 to 729; 4L: 379 to 405).</div></div><div><h3>Conclusion</h3><div>Projections indicate growing burdens of DLBCL and MCL in the US, informing healthcare planning and resource allocation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101291"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theranostic strategies in prostate cancer: Advances in PSMA PET imaging and radioligand therapy","authors":"Talal Al-Assil,&nbsp;John Han,&nbsp;Nazmul Hasan,&nbsp;Spencer Gibson,&nbsp;John Seneriches,&nbsp;Martin Kim,&nbsp;Jena Yang,&nbsp;Shyam Srinivas,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1016/j.ctarc.2026.101293","DOIUrl":"10.1016/j.ctarc.2026.101293","url":null,"abstract":"<div><div>Prostate cancer is the most common solid tumor in males, and it remains a leading cause of cancer-related mortality. Clinicians still struggle to detect early metastatic spread and treat patients whose disease no longer responds to conventional therapy, despite advancements in diagnostics and treatment. Theranostic strategies that target prostate-specific membrane antigen (PSMA) have emerged as a promising strategy to resolve these gaps. PSMA-targeted positron emission tomography (PET) provides superior sensitivity and specificity in comparison to conventional modalities, enabling the detection of recurrent or small-volume disease at low prostate-specific antigen (PSA) levels. Simultaneously, PSMA-directed radioligand therapies, including 177Lu-PSMA-617, have demonstrated advances in progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC), with a manageable toxicity profile. This review emphasizes the significance of PSMA-based imaging and treatment, utilizing evidence from landmark trials. It also looks at changing approaches including early in the disease course through use of theranostics and dual-tracer PET imaging. Strategies using the immunomodulatory effects of radioligand therapy and combination treatments including androgen receptor (AR) pathway inhibitors, chemotherapy, or immunotherapy are under research and may improve outcomes. Furthermore, increasing the range of use of theranostics is the development of next-generation radiotracers and techniques to handle PSMA-negative or neuroendocrine variations. Lastly, we address worldwide differences in access to PSMA-targeted devices defined by manufacturing infrastructure, regulatory diversity, and financing that still hinder use. Fully achieving the potential of theranostics in prostate cancer will depend on improvements in patient selection, treatment sequencing, and equitable implementation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101293"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of glucagon-like peptide 1 receptor and the aggressiveness of extrahepatic cholangiocarcinoma","authors":"Yongyot Varathorn,&nbsp;Mathawee Chanamarnjuntho,&nbsp;Ronnakrit Trakoonsenathong,&nbsp;Charat Kusoltech,&nbsp;Kanyarat Thithuan,&nbsp;Prakasit Sa-ngiamwibool,&nbsp;Charupong Saengboonmee","doi":"10.1016/j.ctarc.2026.101300","DOIUrl":"10.1016/j.ctarc.2026.101300","url":null,"abstract":"<div><div>Previous studies demonstrated that the suppression of GLP-1R expression significantly reduced the aggressiveness of intrahepatic cholangiocarcinoma (iCCA) cells, in vitro and in vivo. However, the clinical significance of GLP-1R in extrahepatic cholangiocarcinoma (eCCA) remains unclear, although this subtype is the most common of bile duct cancer. This study thus aimed to investigate the clinicopathological significance of GLP-1R and to determine its functional roles in eCCA. GLP-1R expression in eCCA tissues was determined using immunohistochemistry. The associations between GLP-1R expression and clinicopathological characteristics and patient survival were examined using univariate analysis and the Kaplan-Meier method with the log-rank test, respectively. Roles of GLP-1R in eCCA cells were investigated using siRNA knockdown, followed by MTT proliferation assays and Transwell migration and invasion assays. Molecular mechanisms were investigated using Western blot analysis. The results showed that high GLP-1R expression was significantly associated with poor histological grading and the mucin production of eCCA (P&lt;0.05). Knockdown of GLP-1R in eCCA cells minimally affected cell proliferation, but significantly suppressed cell migration and invasion (P&lt;0.05). Suppressing GLP-1R expression inhibited epithelial-mesenchymal transition (EMT) in CCA cells and reduced the expression of matrix metalloproteinases 2 and 9. The common upstream regulators of EMT, namely STAT3 and Akt signaling pathways, were also suppressed after GLP-1R silencing. In conclusion, similar to iCCA, high GLP-1R expression is associated with aggressive phenotypes of eCCA. Inhibition of GLP-1R expression might then be another strategy to suppress the progression of CCA in both subtypes.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101300"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of national cancer care network guideline-adherent treatment differences as a contributor to racial disparities in epithelial and non-epithelial ovarian cancer survival","authors":"Marilyn Barragan,&nbsp;Shannon MacLaughlan David,&nbsp;Zhengia Chen,&nbsp;Kimberly Richardson,&nbsp;Wenan Qiang,&nbsp;Denana Miodragovic,&nbsp;Caryn E. Peterson","doi":"10.1016/j.ctarc.2026.101307","DOIUrl":"10.1016/j.ctarc.2026.101307","url":null,"abstract":"<div><h3>Objective</h3><div>To assess National Comprehensive Cancer Network (NCCN) guideline concordance and survival for epithelial and nonepithelial ovarian cancer in Black and White patients. Guideline-concordant care is defined as treatment consistent with NCCN recommendations based on tumor subtype and stage at diagnosis.</div></div><div><h3>Methods</h3><div>This retrospective study included epithelial and nonepithelial ovarian cancer cases from the National Cancer Database from 2005 to 2015 for patients of White or Black race. Outcomes were NCCN guideline concordance and five-year survival following diagnosis. Factors significantly associated with guideline concordance and five-year survival in bivariate analyses were included in multivariable survival models. Survival was assessed using Kaplan–Meier estimates with log-rank tests, and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.</div></div><div><h3>Results</h3><div>Concordance with evidence-based treatment guidelines was lower among Black patients with epithelial histotypes, with no racial difference for nonepithelial types. Black patients also had a higher burden of nonepithelial histotypes relative to White patients. After adjustment for clinical and sociodemographic factors, Black patients had a higher risk of death than White patients (HR = 1.15, 95% CI 1.11–1.18), which was attenuated slightly after inclusion of guideline-concordant treatment in the model (HR = 1.13, 95% CI 1.09–1.17).</div></div><div><h3>Conclusions</h3><div>Guideline-concordant care was associated with racial differences in survival, but the modest association suggests that additional unmeasured factors likely influence outcomes. Limitations include exclusion of cases missing stage, inability to evaluate factors occurring earlier in the treatment trajectory, and absent data regarding the extent of surgical cytoreduction.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101307"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond hyponatremia: serum sodium below 137 mEq/L and postoperative sodium trajectory as prognostic markers in resected non-small cell lung cancer","authors":"Seyda Ors Kaya,&nbsp;Kenan Can Ceylan,&nbsp;Serap Yıldız,&nbsp;Yunus Emre Bal,&nbsp;Yunus Emre Pek,&nbsp;Fehri İlhan,&nbsp;Mustafa Şahin","doi":"10.1016/j.ctarc.2026.101314","DOIUrl":"10.1016/j.ctarc.2026.101314","url":null,"abstract":"<div><h3>Background</h3><div>Clinical hyponatremia (serum sodium &lt;135 mEq/L) is an established adverse prognostic factor in advanced malignancies, but the prognostic significance of serum sodium within the normal range remains unclear in resected non-small cell lung cancer (NSLC). We evaluated whether preoperative serum sodium below 137 mEq/L predicts survival after curative resection.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included 255 patients undergoing curative resection for NSCLC (165 pN0, 90 pN2). Overall survival was the primary endpoint. Preoperative serum sodium was analyzed using Kaplan–Meier analysis and multivariable Cox regression adjusted for age, sex, histology, tumor size, platelet count, and nodal status. One-year postoperative sodium was available in 210 patients for exploratory trajectory analysis.</div></div><div><h3>Results</h3><div>Preoperative sodium &lt;137 mEq/L was present in 56 patients (22.0%) and was associated with shorter median survival than sodium ≥137 mEq/L (32.7 vs. 68.4 months; <em>p</em> = 0.007). After adjustment, sodium &lt;137 mEq/L remained an independent predictor of poor survival (HR=2.02, 95% CI 1.34–3.04; <em>p</em> &lt; 0.001). Patients with sodium 135–136 mEq/L had survival comparable to clinical hyponatremia (&lt;135 mEq/L; <em>p</em> = 0.587) but significantly worse than sodium ≥137 mEq/L (<em>p</em> = 0.001). Exploratory trajectory analysis showed progressively worse survival from the Normal→Normal to the Low→StillLow group (<em>p</em> &lt; 0.001). Postoperative sodium &lt;137 mEq/L was also associated with worse survival in stage I disease (<em>p</em> = 0.017).</div></div><div><h3>Conclusions</h3><div>Preoperative serum sodium below 137 mEq/L is an independent prognostic marker in resected NSCLC. Exploratory postoperative sodium trajectory may provide additional prognostic information and warrants prospective external validation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101314"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma","authors":"Yixuan Lee,&nbsp;Nicole-Ann Lim,&nbsp;Rowena Lee Ying Kwan,&nbsp;Jason Yongsheng Chan","doi":"10.1016/j.ctarc.2026.101312","DOIUrl":"10.1016/j.ctarc.2026.101312","url":null,"abstract":"<div><div>Tumor-agnostic therapies focus on shared molecular biomarkers independent of tissue of origin, allowing a single drug to target a common biomarker across different tumor types. Such targets with regulatory drug approvals include <em>NTRK</em> fusion, <em>RET</em> fusion, BRAF V600E mutation, <em>FGFR1</em> rearrangement, HER2 overexpression, microsatellite instability or mismatch repair deficiency (MSI-H/dMMR), and high tumor mutational burden (TMB-H). Novel strategies against molecular alterations such as <em>NRG1</em> fusion, <em>ALK</em> fusion, <em>MTAP</em> loss, KRAS G12C, TP53 Y220C and homologous repair deficiency (HRD) have also emerged. While the list of potential tumor-agnostic biomarkers continues to expand, contemporary efforts are still predominantly focused on solid cancers over hematological malignancies, including lymphoma, representing a peculiar and perhaps unwarranted strategic gap. In this review, we thus provide a narrative overview of currently approved tumor-agnostic therapies and highlight emerging biomarkers, addressing the need to focus on their potential application beyond solid tumors.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101312"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor Outcomes Across Child-Pugh A, B, and C Hepatocellular Carcinoma: A Real-World Integrated Health-System Cohort","authors":"Alireza Tojjari,&nbsp;Yuming Shi,&nbsp;Stela Celaj,&nbsp;Andy Y. Wu,&nbsp;John Rhee,&nbsp;David A. Geller,&nbsp;Scott W. Biggins,&nbsp;Anwaar Saeed","doi":"10.1016/j.ctarc.2026.101320","DOIUrl":"10.1016/j.ctarc.2026.101320","url":null,"abstract":"<div><h3>Background</h3><div>Pivotal first-line immune checkpoint inhibitor (ICI) trials in advanced hepatocellular carcinoma (HCC) largely restricted enrollment to patients with Child-Pugh A liver function, leaving outcomes in patients with more advanced hepatic dysfunction poorly defined. We evaluated survival, tumor response, and early mortality across Child-Pugh A, B, and C classes in a real-world integrated health-system cohort.</div></div><div><h3>Methods</h3><div>We identified 264 consecutive patients with HCC who received first-line ICI-based systemic therapy at the University of Pittsburgh Medical Center between September 2015 and November 2024, with follow-up through December 2025. Child-Pugh class was re-adjudicated at ICI initiation. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and 90-day mortality.</div></div><div><h3>Results</h3><div>The cohort included 113 patients with Child-Pugh A, 124 with Child-Pugh B, and 27 with Child-Pugh C liver function. Median overall survival was 25.0 months, 13.3 months, and 4.2 months, respectively. Ninety-day mortality was 5.4%, 16.3%, and 40.7%, while objective response rate was 25.5%, 17.0%, and 5.6%. In multivariable Cox regression, Child-Pugh B and C remained independently associated with mortality compared with Child-Pugh A. Among patients who survived at least 90 days, disease control in Child-Pugh C was 38.5%, approaching that observed in Child-Pugh A.</div></div><div><h3>Conclusions</h3><div>In this real-world HCC cohort, worsening Child-Pugh class was associated with progressively shorter survival and higher early mortality after first-line ICI therapy. Although outcomes in Child-Pugh C were poor overall, a subset of patients experienced durable survival or disease control. These findings support careful individualized treatment consideration rather than automatic exclusion of selected Child-Pugh C patients from ICI-based therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"48 ","pages":"Article 101320"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Agrimol B induces apoptosis and ferroptosis in acute monocytic leukemia by targeting EGFR/ERK1/2 signaling and activating SIRT1","authors":"Ting Ma,&nbsp;Qi Wang,&nbsp;Hao Wang,&nbsp;Ke Li,&nbsp;Dan Zhao,&nbsp;Wenjie Huang,&nbsp;Tao Li,&nbsp;Dantong Lyu,&nbsp;Hong Hong,&nbsp;Yue Liu,&nbsp;Min Wang,&nbsp;Jiuqing Gao,&nbsp;Xin Meng,&nbsp;Haiyan Zhang,&nbsp;Xu Wang,&nbsp;Bin Wu","doi":"10.1016/j.ctarc.2026.101441","DOIUrl":"10.1016/j.ctarc.2026.101441","url":null,"abstract":"<div><div>Leukemia is an aggressive hematologic malignancy with high global morbidity and mortality. Despite advances in CAR-T cell therapy and targeted treatments, acute myeloid leukemia and high-risk relapsed cases continue to face formidable therapeutic challenges owing to heterogeneity and drug resistance. Agrimol B (AB), a bioactive natural compound isolated from the edible and medicinal plant <em>Agrimonia pilosa Ledeb</em>., has demonstrated notable anticancer potential. However, its role in leukemia has not yet been investigated. Here, we demonstrate that AB significantly reduces leukemia burden in an Acute Monocytic Leukemia (AMoL) mouse model and suppresses proliferation, invasion, and migration of THP-1 cells in vitro. Mechanistically, AB interacts with EGFR and inhibits ERK1/2 signaling, thereby activating FOXO1. In addition, AB upregulates SIRT1 expression and promotes FOXO1 deacetylation, leading to HMOX1 activation and subsequently triggers ferroptosis. These findings indicate that Agrimol B exerts potent anti-leukemic activity through multiple mechanisms, highlighting its potential as a therapeutic candidate for AMoL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"49 ","pages":"Article 101441"},"PeriodicalIF":3.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}